About the Company
champions oncology, inc. is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs. champions tumorgraft™ technology platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments, or tumorgrafts, in a manner that preserves the biological characteristics of the original human tumor. champions believes that these tumorgrafts, unlike cell line derived xenografts used in tradition testing, closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. the company offers personalized tumorgraft development, drug studies and genome sequencing as part of its personalized oncology solutions ("pos") whereby physicians can evaluate the effects of cancer drugs on their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CSBR News
Champions Oncology Reports Quarterly Revenue of $12.0 Million
HACKENSACK, NJ / ACCESSWIRE / March 12, 2024 / (NASDAQ:CSBR), a global preclinical and clinical research services provider ...
Champions Oncology, Inc. (CSBR) Q3 2024 Earnings Call Transcript
Greetings. Welcome to the Champions Oncology Third Quarter Fiscal Year 2024 Earnings Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the ...
Champions Oncology's US Laboratory has Acquired Distinguished CAP Accreditation
HACKENSACK, NJ / ACCESSWIRE / March 7, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, announced ...
Champions Oncology Inc.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
‘Champions,’ ‘The Witcher: Blood Origin,’ ‘All the Light We Cannot See’ Among Ruderman Family Foundation Awardees for Inclusion
Champions' and 'The Witcher' are among the film and TV projects honored by the Ruderman Foundation for authentic portrayals ...
Bellator Champions Series: Belfast – Make your predictions for two title fights
Those MMA Junkie reader consensus picks will be part of the Bellator Champions Series: Belfast main card staff predictions we ...
Ben Chan still in it to win it after Game 5 of 'Jeopardy!' Tournament of Champions; thanks local brewery, beloved dive bar
The Green Bay champion thanked the local places that have hosted his watch parties, including longtime dive bar St. Michael's ...
Champions Oncology Reports Quarterly Revenue of $12.0 Million
About Champions Oncology, Inc. Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the ...
Champions Oncology, Inc.: Champions Oncology's US Laboratory has Acquired Distinguished CAP Accreditation
HACKENSACK, NJ / ACCESSWIRE / March 7, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, announced ...
Champions Oncology, Inc.: Champions Oncology Reports Quarterly Revenue of $12.0 Million
HACKENSACK, NJ / / March 12, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced ...
Loading the latest forecasts...